The most-clicked news item for Thursday was “Pharma shares sink as U.S. threatens tax-inversion crackdown.” The US Treasury Department has announced that it is looking into undisclosed measures to discourage tax inversions. This could have a big impact on the pharma industry, as several are looking to follow the lead of previous companies such as AbbVie in purchasing overseas companies that would provide tax benefits.
Ebola continues to make headlines. A CP Wire piece, “Ebola drug developer Tekmira trading halted,” was the second most popular link Thursday. Trading of Tekmira’s stock was halted at 4:00 PM Thursday, followed soon by news that the FDA would be allowing for the potential of Tekmira’s clinical trials of TKM-Ebola to resume for infected patients. The FDA had suspended the human trials last month due to safety concerns.
The third most popular news item was “Dealpolitik: Did Valeant Make a Strategic Error in Its Allergan Bid?” This WSJ piece discusses the strategic issues surrounding the not-yet-successful hostile bid for Allergan, and how the involvement of Ackman’s Pershing Square Capital may have had a negative impact.
The fourth most-clicked link was a Boston Business Journal piece “Why a bigger deal hasn't been made of the world's first approval of a Duchenne drug.” It speculates why this week’s European approval of the PTC Therapeutics drug Translarna has not received much press even though Duchenne muscular dystrophy is a hot media topic.